NORMOCARB HF 25 Drug Patent Profile

When do Normocarb Hf 25 patents expire, and when can generic versions of Normocarb Hf 25 launch?

Normocarb Hf 25 is a drug marketed by Dialysis Sups and is included in one NDA.

The generic ingredient in NORMOCARB HF 25 is magnesium chloride; sodium bicarbonate; sodium chloride. There are one hundred and forty-six drug master file entries for this compound. Additional details are available on the magnesium chloride; sodium bicarbonate; sodium chloride profile page.

Summary for NORMOCARB HF 25

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	NORMOCARB HF 25 at DailyMed

US Patents and Regulatory Information for NORMOCARB HF 25

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dialysis Sups	NORMOCARB HF 25	magnesium chloride; sodium bicarbonate; sodium chloride	SOLUTION;INJECTION	021910-001	Jul 26, 2006		RX	Yes	Yes

Expired US Patents for NORMOCARB HF 25

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Dialysis Sups	NORMOCARB HF 25	magnesium chloride; sodium bicarbonate; sodium chloride	SOLUTION;INJECTION	021910-001	Jul 26, 2006
Dialysis Sups	NORMOCARB HF 25	magnesium chloride; sodium bicarbonate; sodium chloride	SOLUTION;INJECTION	021910-001	Jul 26, 2006

International Patents for NORMOCARB HF 25

See the table below for patents covering NORMOCARB HF 25 around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2620902
Canada	2365787	SOLUTIONS CONCENTREES STERILES FAIBLES EN BICARBONATE POUR DIALYSE (STERILE LOW BICARBONATE DIALYSIS CONCENTRATE SOLUTIONS)
European Patent Office	1347795
World Intellectual Property Organization (WIPO)	0249693

Supplementary Protection Certificates for NORMOCARB HF 25

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1020461	C300482	Netherlands		PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20101105
0124495	SPC/GB01/006	United Kingdom		PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
1499331	C300615	Netherlands		PRODUCT NAME: NATRIUMSULFAAT, MAGNESIUMSULFAAT EN KALIUMSULFAAT; NAT. REGISTRATION NO/DATE: RVG 110863 20130417; FIRST REGISTRATION: BE 434323 20130220
1499331	13C0055	France		PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220
0984957	C300483	Netherlands		PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMTRIHYFRAAT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20110524
0984957	C300517	Netherlands		PRODUCT NAME: ACETYLSALICYLZUUR EN ESOMEPRAZOLMAGNESIUMTRIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 107516 20110912; FIRST REGISTRATION: 540235954023675402375 2011120812

NORMOCARB HF 25 Market Dynamics and Financial Trajectory: Pricing, Demand, Competition, and IP-Driven Risk

Last updated: July 30, 2026

NORMOCARB HF 25 is a branded “HF” product in the Normocarb portfolio. Public market analytics and financial reporting tied specifically to “NORMOCARB HF 25” are not identifiable at the product-label level from standard, widely indexed sources. As a result, there is no auditable way to produce a complete, accurate market sizing, revenue curve, payer mix, launch timing, or forecast anchored to this exact SKU.

What is NORMOCARB HF 25 and what products does it compete against?

NORMOCARB HF 25 is marketed under the Normocarb brand as a “HF” line extension at a “25” strength/grade level. In the absence of verifiable, source-indexed product identifiers (FDA NDC, INN/active ingredient, dosage form, manufacturer, and application type), the competitive set cannot be mapped with precision.

What active ingredient and dosage form does NORMOCARB HF 25 use?

A product-level competitive and financial analysis requires:

• the INN/active ingredient(s),
• dosage form (tablet, capsule, suspension, powder, etc.),
• strength (the “25” label alone is not sufficient to identify the pharmacologic entity),
• the manufacturer/labeler.

Without that, any competitor mapping would be speculative.

What is the likely therapeutic category?

“Hf” is not a standard, unique therapeutic shorthand across pharmaceuticals and may refer to product lineage, formulation, or internal classification. Without verified labeling, category placement cannot be confirmed.

How does demand typically evolve for NORMOCARB HF 25 in its first 3–5 years?

A credible demand trajectory is driven by:

• launch and ramp schedule,
• formulary access (P&T committee outcomes),
• payer coverage and prior authorization requirements,
• substitution risk from therapeutically equivalent products,
• safety and tolerability signals.

Because NORMOCARB HF 25 product launch timing and coverage status are not verifiable from indexed sources, a data-backed ramp curve cannot be constructed.

What are the pricing dynamics and payer reimbursement risks for NORMOCARB HF 25?

Pricing and reimbursement models depend on:

• whether the product is reimbursed through U.S. commercial plans, Medicare Part D, or Medicaid,
• whether it has an ASP/NADAC-based reimbursement anchor,
• whether it sits in a specialty pharmacy, hospital, or retail channel,
• presence of therapeutically equivalent generics or substitutes.

A product-level pricing model cannot be quantified without NDC-level identification and payer adjudication data.

How strong is the patent estate for NORMOCARB HF 25 and how does it affect revenue?

Patent-driven revenue protection requires:

• the listed active ingredient(s) and the associated Orange Book entry (if applicable),
• patent numbers, application numbers, and expiration dates,
• exclusivity periods (NCE, 3-year, 7-year, 180-day, patent-term adjustment).

No auditable Orange Book or jurisdiction-specific patent bundle can be tied to “NORMOCARB HF 25” from the provided topic alone.

When does NORMOCARB HF 25 lose exclusivity and what generic entry risks exist?

Exclusivity and generic entry risk analysis requires:

• Orange Book listing status,
• patent expiry and listed patent scopes,
• whether any ANDA Paragraph IV challenges exist,
• litigation/settlement agreements and trigger dates.

No product-accurate exclusivity timeline can be produced.

What patent litigation or regulatory events could change NORMOCARB HF 25 sales?

Regulatory and litigation events that typically shift sales include:

• FDA warning letters tied to manufacturing,
• REMS changes or label restrictions,
• patent infringement suits over formulation or method-of-use,
• settlement dates enabling at-risk launches.

No litigation docket or FDA event chain can be associated with this exact SKU with sufficient identification accuracy.

How does NORMOCARB HF 25 compare financially with close alternatives?

A financial comparison requires:

• competitor list by active ingredient,
• comparable strength and formulation,
• pricing benchmarks and utilization measures,
• market share by channel and geography.

Because NORMOCARB HF 25’s active ingredient and jurisdiction-specific market definition cannot be confirmed, a like-for-like competitor comparison would be non-actionable.

Geographic market dynamics: where does NORMOCARB HF 25 sell and how do rules differ?

Geographic dynamics depend on:

• regulatory approvals (EMA/NMPA/FDA or country-specific),
• reimbursement and HTA outcomes (NICE/ICER equivalents),
• import controls and pricing regulations.

No verified approved-market geography can be mapped for this SKU.

Commercial trajectory drivers: what metrics should be tracked for NORMOCARB HF 25?

For a drug with identifiable regulatory labeling, the standard metric set is:

• net sales by month/quarter,
• prescription volume and average selling price trajectory,
• rebate intensity (commercial) or dispensing fees (public),
• formulary placement rate and tier status,
• share loss to generics/biosimilars,
• inventory and gross-to-net conversion.

This metric set cannot be populated for NORMOCARB HF 25 without source-identifiable product reporting.

Key Takeaways

• A product-specific market and financial trajectory for “NORMOCARB HF 25” cannot be produced from available indexed identification signals at the SKU level.
• Patent and exclusivity assessment, including Orange Book status, Paragraph IV risk, and litigation triggers, cannot be mapped to this exact product label without verifiable drug identifiers.

FAQs

1. What NDC (or local regulatory code) identifies NORMOCARB HF 25 for market tracking?
2. What active ingredient(s) and strength does “HF 25” correspond to for competitive substitution risk?
3. Is NORMOCARB HF 25 listed in the FDA Orange Book, and which patents are associated?
4. Are there any Paragraph IV ANDA challenges or infringement settlements tied to NORMOCARB HF 25’s formulation or use?
5. Which payer channels (specialty vs retail) drive NORMOCARB HF 25 net sales and gross-to-net dynamics?

References

No sources were used because no product-identifiable dataset could be reliably matched to “NORMOCARB HF 25.”